FDA clears first drug for blindness sleep disorder

U.S. health regulators have approved a first-of-a-kind drug to treat a sleep disorder that mainly afflicts the blind.

The Food and Drug Administration approved Hetlioz capsules for patients who have problems sleeping because they can't detect light. The condition, called non-24-hour disorder, is estimated to affect up to 100,000 Americans, most of whom are totally blind. Hetlioz is the first FDA-approved treatment for the condition.

The most common side effects of the drug include headache, nightmares and respiratory and . The drug labeling warns that Hetlioz causes drowsiness and can interfere with performing basic tasks and mental alertness.

Analysts estimate the drug's annual sales could exceed $350 million.

Washington DC-based Vanda Pharmaceuticals markets one other drug for schizophrenia.

Company shares rose nearly 5 percent in afternoon trading.

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

US health watchdog rejects Sanofi's MS drug

Dec 30, 2013

French drug giant Sanofi announced Monday US health authorities had rejected its Lemtrada drug for some forms of multiple sclerosis, which is already approved in the European Union, Canada and Australia.

Recommended for you

Most US babies get their vaccines, CDC says

Aug 28, 2014

(HealthDay)—The vast majority of American babies are getting the vaccines they need to protect them from serious illnesses, federal health officials said Thursday.

Expression of privilege in vaccine refusal

Aug 27, 2014

Not all students returning to school this month will be up to date on their vaccinations. A new study conducted by Jennifer Reich, a researcher at the University of Colorado Denver, shows that the reasons why children may ...

User comments